Skip to main content

Compare Stocks

Date Range: 

 Kezar Life SciencesTrevenaOramed PharmaceuticalsInfinity PharmaceuticalsTheratechnologies
SymbolNASDAQ:KZRNASDAQ:TRVNNASDAQ:ORMPNASDAQ:INFIOTCMKTS:THERF
Price Information
Current Price$5.24$1.52$10.30$2.72$3.51
52 Week RangeBuyBuyBuyBuyN/A
MarketRank™
Overall Score1.31.31.31.60.5
Analysis Score3.33.43.54.40.0
Community Score2.13.33.12.02.4
Dividend Score0.00.00.00.00.0
Ownership Score0.80.00.00.80.0
Earnings & Valuation Score0.00.00.00.60.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyN/A
Consensus Price Target$15.00$5.00$20.25$9.00N/A
% Upside from Price Target186.26% upside228.95% upside96.60% upside230.88% upsideN/A
Trade Information
Market Cap$251.94 million$248.66 million$311.35 million$241.12 million$270.11 million
Beta0.332.591.982.40.58
Average Volume282,2133,697,290710,7373,151,29145,196
Sales & Book Value
Annual RevenueN/A$30,000.00$2.71 million$3.05 million$45.18 million
Price / SalesN/A8,288.71114.8979.065.98
CashflowN/AN/AN/AN/A$0.02 per share
Price / CashN/AN/AN/AN/A177.07
Book Value$4.08 per share$0.32 per share$1.40 per share$0.14 per share$0.47 per share
Price / BookN/A4.757.3619.437.47
Profitability
Net Income$-35,090,000.00$-24,870,000.00$-11,510,000.00$-47,060,000.00$-4,660,000.00
EPS($1.84)($0.27)($0.56)($0.83)N/A
Trailing P/E RatioN/AN/AN/AN/A0.00
Forward P/E RatioN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/A-424.76%-2,592.65%-11.57%
Return on Equity (ROE)-31.71%-42.49%-45.93%-1,358.77%-14.31%
Return on Assets (ROA)-29.17%-34.83%-30.33%-81.85%-4.25%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/A1.70%
Current Ratio24.84%28.08%8.93%4.42%2.69%
Quick Ratio24.84%28.08%8.93%4.42%2.19%
Ownership Information
Institutional Ownership Percentage49.51%11.62%6.03%46.66%1.37%
Insider Ownership Percentage7.60%5.20%16.10%13.77%N/A
Miscellaneous
Employees4725N/A2332
Shares Outstanding48.08 million163.59 million30.23 million88.65 million76.95 million
Next Earnings Date8/4/2021 (Estimated)8/9/2021 (Estimated)7/6/2021 (Estimated)7/29/2021 (Estimated)N/A
OptionableNot OptionableOptionableOptionableOptionableNot Optionable
SourceHeadline
Theratechnologies (OTCMKTS:THERF) Share Price Passes Below 50 Day Moving Average of $3.58Theratechnologies (OTCMKTS:THERF) Share Price Passes Below 50 Day Moving Average of $3.58
americanbankingnews.com - April 27 at 3:38 AM
Hedge Fund and Insider Trading News: Bill Ackman, Michael Platt, Vivid Capital Management, Tiger Global Management, Lemonade Inc (LMND), Theratechnologies Inc (THTX), and MoreHedge Fund and Insider Trading News: Bill Ackman, Michael Platt, Vivid Capital Management, Tiger Global Management, Lemonade Inc (LMND), Theratechnologies Inc (THTX), and More
feedproxy.google.com - January 22 at 2:11 PM
Theratechnologies to Present at the Piper Sandler Virtual Healthcare ConferenceTheratechnologies to Present at the Piper Sandler Virtual Healthcare Conference
financialpost.com - November 23 at 4:19 PM
Theratechnologies Inc. (THTX) Q3 2020 Earnings Call TranscriptTheratechnologies Inc. (THTX) Q3 2020 Earnings Call Transcript
fool.com - October 15 at 5:45 PM
Theratechnologies Confirms Issuance of U.S. Patent Covering the Use of Tesamorelin in the Treatment of Individuals Suffering From NAFLD/NASHTheratechnologies Confirms Issuance of U.S. Patent Covering the Use of Tesamorelin in the Treatment of Individuals Suffering From NAFLD/NASH
feeds.benzinga.com - October 13 at 5:28 PM
Theratechnologies EPS beats by $0.02, misses on revenueTheratechnologies EPS beats by $0.02, misses on revenue
seekingalpha.com - October 8 at 8:16 AM
Theratechnologies Inc. (THERF) CEO Luc Tanguay on Q2 2019 Results - Earnings Call TranscriptTheratechnologies Inc. (THERF) CEO Luc Tanguay on Q2 2019 Results - Earnings Call Transcript
seekingalpha.com - July 11 at 4:40 PM
Theratechnologies, Inc. to Host Earnings CallTheratechnologies, Inc. to Host Earnings Call
finance.yahoo.com - July 11 at 10:00 AM
Theratechnologies Inc. (THERF) CEO Luc Tanguay on Q1 2019 Results - Earnings Call TranscriptTheratechnologies Inc. (THERF) CEO Luc Tanguay on Q1 2019 Results - Earnings Call Transcript
seekingalpha.com - April 4 at 5:34 PM
Theratechnologies And NASH In HIV Patients, And The Market AssessmentTheratechnologies And NASH In HIV Patients, And The Market Assessment
seekingalpha.com - March 21 at 5:27 PM
Theratechnologies rises as Europe certifies its Chinese manufacturing facilitiesTheratechnologies rises as Europe certifies its Chinese manufacturing facilities
www.proactiveinvestors.com - March 21 at 9:14 AM
Theratechnologies And Egrifta In NASH: A Hidden Gem With Broad Therapeutic PotentialTheratechnologies And Egrifta In NASH: A Hidden Gem With Broad Therapeutic Potential
seekingalpha.com - March 14 at 5:26 PM
Theratechnologies Inc. (THERF) CEO Luc Tanguay on Q4 2018 Results - Earnings Call TranscriptTheratechnologies Inc. (THERF) CEO Luc Tanguay on Q4 2018 Results - Earnings Call Transcript
seekingalpha.com - February 22 at 5:22 PM
DateCompanyBrokerageAction
3/15/2021Kezar Life SciencesHC WainwrightReiterated Rating
6/14/2020Kezar Life SciencesCowenReiterated Rating
6/14/2020Kezar Life SciencesWells Fargo & CompanyReiterated Rating
3/13/2020Kezar Life SciencesWilliam BlairReiterated Rating
7/16/2018Kezar Life SciencesJefferies Financial GroupInitiated Coverage
3/22/2021TrevenaOppenheimerInitiated Coverage
9/14/2020TrevenaGuggenheimInitiated Coverage
8/27/2020TrevenaCantor FitzgeraldInitiated Coverage
10/12/2018TrevenaJMP SecuritiesBoost Price Target
10/12/2018TrevenaNeedham & Company LLCDowngrade
4/27/2021Oramed PharmaceuticalsAlliance Global PartnersBoost Price Target
4/26/2021Oramed PharmaceuticalsCanaccord GenuityInitiated Coverage
2/15/2021Oramed PharmaceuticalsAegisReiterated Rating
2/9/2021Oramed PharmaceuticalsNational SecuritiesInitiated Coverage
9/11/2019Oramed PharmaceuticalsLADENBURG THALM/SH SHInitiated Coverage
7/16/2018Oramed PharmaceuticalsB. RileyDowngrade
3/24/2021Infinity PharmaceuticalsTruist SecuritiesInitiated Coverage
3/18/2021Infinity PharmaceuticalsTruist FinancialInitiated Coverage
2/25/2021Infinity PharmaceuticalsPiper SandlerInitiated Coverage
2/5/2021Infinity PharmaceuticalsJPMorgan Chase & Co.Upgrade
6/27/2019Infinity PharmaceuticalsCIBCInitiated Coverage
1/7/2019Infinity PharmaceuticalsUBS GroupReiterated Rating
10/9/2019TheratechnologiesRoyal Bank of CanadaSet Price Target
10/9/2019TheratechnologiesMackieReiterated Rating
(Data available from 5/15/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.